Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Vytorin/Inegy ezetimibe/simvastatin: Phase III ongoing

The partners said they will not change the primary endpoint of the Phase III ENHANCE trial of Vytorin/Inegy despite the advice from

Read the full 224 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE